next agonist
The beachhead: the narrow uses that could open the door for everyone
Analysis — but this one is anchored to trials that are actually running.
The leap from “treats a rare disease” to “protects the general public” almost never happens in a single jump. It happens through beachheads: narrower indications where the benefit-risk math already works, each one building the safety record, the manufacturing base, and the delivery experience the next step will need. GLP-1 drugs spent years as diabetes treatments before the evidence and the nerve existed to bring them to the far larger population that wanted them for weight.
A melanocortin photoprotective has its own ladder of beachheads — and, unlike the general-public drug, several of its rungs are real and occupied right now.
The rungs that already exist
Erythropoietic protoporphyria. The first beachhead, already taken. Afamelanotide — chemically the original Melanotan I — is approved for EPP (the middle-ground agonist already exists). It proved the target is druggable, the molecule approvable, and a melanocortin implant manufacturable and shippable.
Vitiligo. This is the live one, and it matters. Clinuvel — the company that developed afamelanotide — is running a global Phase III trial (designated CUV105) testing afamelanotide alongside narrowband-UVB phototherapy to repigment vitiligo, with more than 200 patients enrolled as of 2025 and first results expected in the second half of 2026. Vitiligo is another pigment indication, in a substantially larger population than EPP, and a genuine test of a melanocortin drug doing pigment work in otherwise ordinary skin. It is the clearest sign that the molecule is being walked deliberately up the ladder.
The rungs that would make sense next
These aren’t announced programs — they’re where the benefit-risk logic points if the ladder keeps climbing:
- Organ-transplant recipients, whose lifelong immunosuppression drives skin-cancer rates far above the general population’s. Strong prevention rationale, and a risk tolerance to match it.
- Inherited high-risk groups — xeroderma pigmentosum, familial atypical multiple mole–melanoma syndrome, and other genetic photosensitivity and melanoma-predisposition conditions.
- Other photodermatoses — polymorphic light eruption and related sun-driven diseases.
Each is a population where “reduce ultraviolet damage” is plainly worth more than it costs — which is exactly the condition a trial needs to be runnable and approvable.
Why this is the optimistic read
The general-public tanning-and-protection drug is still speculative — labeled hope, as this pillar always labels it. But the beachheads are not hypothetical. A melanocortin pigment drug is, right now, being pushed from a rare disease into a more common one, by a company that has cleared the regulatory path before. Clinuvel is even exploring the same molecule in early Parkinson’s disease — a sign the field keeps finding new ground under it.
The path to “everyone” runs through a long series of “someones,” and someone is walking it. That — not a vial, not a forum protocol, not a promise — is the most concrete reason for optimism the honest version of this story allows.